In Kaituo Pharmaceuticals-B (09939): KX-826 announced the Phase III clinical trial data and combination therapy research for treating androgenetic alopecia in WCHR 2026, and was selected for an outstanding poster award.

Intelligence Finance APP News, Kotler Pharmaceutical-B (09939) announced that its self-developed and potentially pioneering KX-826 will be presented at the 14th World Congress for Hair Research (WCHR 2026) held in Seoul, South Korea from May 28th to 31st, 2026. Two important clinical research data were announced: (i) Phase III clinical trial data for treating androgenetic alopecia (AGA or hair loss) in Chinese adult males. The principal investigator of this Phase III clinical trial, Professor Zhou Cheng from Peking University People's Hospital, presented the final analysis results of the efficacy and safety of KX-826 1.0% in treating hair loss in Chinese adult males. The overall results showed excellent effectiveness and safety of KX-826 in treating hair loss patients. Additionally, the results of this Phase III clinical trial were selected as an Outstanding Poster at the 14th World Congress for Hair Research. (ii) Clinical observational trial research data on the combined treatment of androgenetic alopecia in Chinese adult males with minoxidil. This clinical observational trial, led by Professor Jiang Leiwei, will provide a solid basis for future Phase III clinical trials on the combined therapy of KX-826 and minoxidil.